Activation of inflammation and coagulation after infusion of C-reactive protein in humans.

Bisoendial, Radjesh J; Kastelein, John J P; Levels, Johannes H M; Zwaginga, Jaap J; van den Bogaard, Bas; Reitsma, Pieter H; Meijers, Joost C M; Hartman, Daniel et al. · Circ Res · 2005

case_series · Level IV

Where this comes from

Abstract

C-reactive protein (CRP) has been postulated to play a causal part in atherosclerosis and its acute complications. We assessed the effects of CRP-infusion on coagulation and inflammatory pathways to determine its role in atherothrombotic disease. Seven male volunteers received an infusion on two occasions, containing 1.25 mg/kg recombinant human CRP (rhCRP) or diluent, respectively. CRP-concentrations rose after rhCRP-infusion from 1.9 (0.3 to 8.5) to 23.9 (20.5 to 28.1) mg/L, and subsequently both inflammation and coagulation were activated. This sequence of events suggests that CRP is not only a well known marker of cardiovascular disease, but is also probably a mediator of atherothrombotic disease.

Medical subject headings